Logo

American Heart Association

  2
  0


Final ID: MDP1198

Resistant Hypertension and Mortality

Abstract Body (Do not enter title and authors here): Background: Resistant hypertension is characterized by the persistence of elevated office or clinic blood pressure despite the use of three antihypertensive agents. Ambulatory blood pressure monitoring helps to distinguish between true (24-hour blood pressure ≥ 130 or ≥ 80 mmHg) and white-coat (24-hour blood pressure < 130/80 mmHg) resistant hypertension. The aim of the study was to evaluate the risk of all-cause and cardiovascular mortality in resistant hypertension as compared to controlled hypertension, as well as in true versus white-coat resistant hypertension.

Methods: From the Spanish Ambulatory Blood Pressure Registry, we selected 8146 patients with controlled hypertension (office blood pressure < 140/90 mmHg while on treatment with three or less antihypertensive drugs), and 8577 with resistant hypertension (office blood pressure ≥ 140 or ≥ 90 mmHg while on treatment with 3 or more antihypertensive drugs). All-cause and cardiovascular mortality (median follow-up 9.7 years) were compared between both groups as well as between patients with white-coat (3289) and true (5288) resistant hypertension. Hazard ratios from Cox models unadjusted and after adjustment for clinical confounders were used for such comparisons.

Results: Compared to controlled hypertension, resistant hypertension was associated with an increased risk in all-cause mortality (hazard ratio [HR]: 1.21; 95% CI: 1.12-1.30) and cardiovascular mortality (1.33; 1.17-1.51) in confounder-adjusted models. Compared to white-coat resistant hypertension, true resistant hypertension was also associated with an increased risk of all-cause (1.45; 1.32-1.60) and cardiovascular (1.68; 1.43-1.98) mortality. When true and white-coat resistant hypertension were separately compared with controlled hypertension, true, but not white-coat resistant hypertension was associated with an increased risk of all-cause and cardiovascular mortality.

Conclusion: Resistant hypertension is associated with an increased risk of all-cause and cardiovascular mortality with respect to controlled hypertension. Moreover, 24-h blood pressure is a powerful determinant of risk in resistant hypertension.
  • Dela Sierra, Alejandro  ( HOSPITAL MUTUA TERRASSA , Terrassa , Spain )
  • Ruilope, Luis  ( Hospital 12 de Octubre , Madrid , Spain )
  • Staplin, Natalie  ( Oxford University , Oxford , United Kingdom )
  • Gorostidi, Manuel  ( Hospital Central de Asturias , Oviedo , Spain )
  • Vinyoles, Ernest  ( CAP La Mina , Sant Adria de Besos , Spain )
  • Segura, Julian  ( Hospital 12 de Octubre. , Madrid , Spain )
  • Armario, Pedro  ( L HOSPITALET DELLOBREGAT , Barcelona , Spain )
  • Oliveras, Anna  ( Hospital del Mar , Barcelona , Spain )
  • Williams, Bryan  ( University College London , London , United Kingdom )
  • Author Disclosures:
    Alejandro DeLa Sierra: DO NOT have relevant financial relationships | Luis Ruilope: DO NOT have relevant financial relationships | Natalie Staplin: DO have relevant financial relationships ; Research Funding (PI or named investigator):Boehringer Ingelheim:Active (exists now) ; Research Funding (PI or named investigator):Novo Nordisk:Active (exists now) ; Research Funding (PI or named investigator):Eli Lilly:Past (completed) | Manuel Gorostidi: DO NOT have relevant financial relationships | Ernest Vinyoles: DO NOT have relevant financial relationships | Julian Segura: DO have relevant financial relationships ; Advisor:Astrazeneca:Active (exists now) ; Speaker:Vifor:Past (completed) ; Speaker:Servier:Past (completed) ; Speaker:Novonordisk:Past (completed) ; Speaker:MSD:Past (completed) ; Speaker:Menarini:Past (completed) ; Advisor:Bayer:Active (exists now) | Pedro Armario: No Answer | Anna Oliveras: No Answer | Bryan Williams: DO have relevant financial relationships ; Advisor:Novartis:Active (exists now) ; Executive Role:British Heart Foundation:Active (exists now) ; Advisor:astra Zeneca:Active (exists now) ; Speaker:Servier:Past (completed)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

The Threats of Hypertension to Life and Healthy Organ Function

Sunday, 11/17/2024 , 09:30AM - 10:45AM

Moderated Digital Poster Session

More abstracts on this topic:
Chromophobe Renal Cell Carcinoma Presenting as Hypertension in a Young Adult: A Case Report

Al Kayed Hadeel, Alqatawneh Maryam, Maaita Mahmoud, Alsuradi Awni, Odaibat Husam

Correlation between plasma CT-proET-1 and renal dysfunction in patients with resistant hypertension. A biomarker analysis of the PRECISION study.

Blattmann Peter, Iglarz Marc, Dreier Roland, Danaietash Parisa, Sassi-sayadi Mouna, Clozel Martine

More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available